Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Silexion Therapeutics ( (SLXN) ) has provided an update.
On May 22, 2025, Silexion Therapeutics Corp, a Cayman Islands exempted company, received a delisting notice from the Nasdaq Listing Qualifications Department due to non-compliance with specific Nasdaq Listing Rules. The company had previously been granted a 180-day compliance period, which ended on May 19, 2025, but failed to meet the required market value thresholds. Silexion intends to appeal the decision and is considering transferring its listing to the Nasdaq Capital Market, although success is not guaranteed.
The most recent analyst rating on (SLXN) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.
Spark’s Take on SLXN Stock
According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.
Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.
To see Spark’s full report on SLXN stock, click here.
More about Silexion Therapeutics
Average Trading Volume: 4,461,928
Technical Sentiment Signal: Sell
Current Market Cap: $8.57M
See more data about SLXN stock on TipRanks’ Stock Analysis page.